Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:PACB) with a Sector Outperform and lowers the price target from $8 to $7.
- Headlines
- Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
11:48
Soochow: Bullish on the Insurance industry’s competitive advantage in the Silver economy era.
Soochow-2.50%
11:41
Musk and the Tesla Board of Directors have been granted permission to appeal the $56 billion compensation plan.
TSLA+4.34%
11:41
The Israeli army has destroyed water and electricity facilities in the southern Quneitra province of Syria.